Raltegravir ( DrugBank: Raltegravir )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2
26	HTLV-1関連脊髄症	4
93	原発性胆汁性胆管炎	1
265	脂肪萎縮症	2

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01767701 (ClinicalTrials.gov)	April 2013	7/1/2013	Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis	A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir(Isentress) in Pr ...	Relapsing Remitting Multiple Sclerosis	Drug: Raltegravir	Queen Mary University of London	Merck Sharp & Dohme Corp.	Completed	18 Years	55 Years	All	23	Phase 2	United Kingdom
2	EUCTR2012-004847-61-GB (EUCTR)	16/01/2013	18/12/2012	INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS	A phase II baseline versus treatment study to determine the efficacy of raltegravir(ISENTRESS) in pr ...	Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;T ...	Trade Name: ISENTRESS Product Name: raltegravir INN or Proposed INN: lactose monohydrate	Queen Mary University of London	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	United Kingdom

First Previous1Next Last

26. HTLV-1関連脊髄症

臨床試験数 : 29 / 薬物数 : 47 - (DrugBank : 29) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 119

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02655471 (ClinicalTrials.gov)	July 1, 2017	16/11/2015	Effect of Raltegravirin Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Viru ...	Effect of Raltegravirin Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infect ...	HTLV-I Infections;Tropical Spastic Paraparesis	Drug: Raltegravir and Zidovudine	Universidad Peruana Cayetano Heredia	Merck Sharp & Dohme Corp.	Completed	18 Years	N/A	All	10	Early Phase 1	Peru
2	NCT01867320 (ClinicalTrials.gov)	September 5, 2013	21/5/2013	Raltegravir for HAM/TSP	Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) As ...	HTLV-I Infection	Drug: Raltegravir	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	N/A	All	19	Early Phase 1	United States
3	NCT01620736 (ClinicalTrials.gov)	January 2012	25/1/2012	Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load	Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load	Human T-cell Leukemia Virus Type 1 Infection	Drug: Raltegravir	Washington University School of Medicine	Merck Sharp & Dohme Corp.	Withdrawn	18 Years	N/A	All	0	Phase 2	United States
4	NCT01000285 (ClinicalTrials.gov)	September 2010	19/10/2009	EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma	Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibit ...	Leukemia-Lymphoma, Adult T-Cell	Drug: Bortezomib;Drug: Etoposide;Drug: Vincristine;Drug: Doxorubicin;Drug: Prednisone;Drug: Cyclopho ...	Washington University School of Medicine	NULL	Completed	18 Years	N/A	All	18	Phase 1/Phase 2	United States

First Previous1Next Last

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03954327 (ClinicalTrials.gov)	June 29, 2020	7/5/2019	Combination Antiretroviral Therapy (cART) for PBC	Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravirfor Patients ...	Primary Biliary Cholangitis	Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF);Drug: Raltegravir;Drug: Placebo Oral Capsule [C ...	University of Alberta	Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	All	60	Phase 2	Canada

First Previous1Next Last

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01164605 (ClinicalTrials.gov)	October 2010	14/7/2010	Pilot Study of Raltegravir Lipodystrophy IISP	Pilot Study on the Efficacy of a Two Drug, Raltegravir-based Regimen,(NRTI) Sparing Antiretroviral T ...	HIV Infection	Drug: Raltegravir	Southern California Institute for Research and Education	Merck Sharp & Dohme Corp.	Recruiting	N/A	N/A	Both	30	N/A	United States
2	NCT00656175 (ClinicalTrials.gov)	September 2008	2/4/2008	Raltegravir Therapy for Women With HIV and Fat Accumulation	Phase II Study of Raltegraviras Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcr ...	HIV Infections;Lipodystrophy	Drug: raltegravir	University of California, Los Angeles	Merck Sharp & Dohme Corp.;Case Western Reserve University;Vanderbilt University;Tufts University;Uni ...	Completed	18 Years	N/A	Female	39	Phase 2	United States;Canada

First Previous1Next Last

先頭へ